Search Results for "Hydrocodone Bitartrate 7 5 Mg"

23:15 EDT 28th March 2017 | BioPortfolio

Matching Channels


Matching News

FDA approves Lupin’s hydrocodone bitartrate, acetaminophen tablets

David SalazarThe Food and Drug Administration has approved a generic of Mikart’s hydrocodone bitartrate and acetaminophen tablets from Gavis Pharmaceuticals, Lupin’s U.S. subsidiary, the c...

Teva Receives FDA Approval for Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology

JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved Vantrela ER (hydrocodone bita...

Perrigo Announces FDA Final Apffproval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution

Lupin launches Hydrocodone Bitartrate generic

Brian BerkIt is indicated for the relief of moderate to moderately severe pain. read more

FDA approves Perrigo’s hydrocodone bitartrate and homatropine methylbromide

Brian BerkThe solutions are indicated for the symptomatic relief of cough in adults and children 6 years of age and older. read more

Generic pain drug launched by Lupin

The AA-rated generic version of Mikart's Hydrocodone Bitartrate and Acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and -More- 

FDA thumbs up for Teva’s abuse-deterrent pain drug

The US Food and Drug Administration has approved Vantrela ER (hydrocodone bitartrate) extended-release…

FDA approves Teva's abuse-deterrent opioid

Teva Pharmaceutical Industries' Vantrela ER, or hydrocodone bitartrate extended-release tablet, has been approved by the FDA  -More- 

Matching PubMed Articles

Hydrocodone Bitartrate ER (Hysingla(®) ER): A Review in Chronic Pain.

Hydrocodone bitartrate extended-release (Hysingla(®) ER; referred to hereafter as hydrocodone ER) was the first single-entity hydrocodone formulation recognized by the US FDA as having abuse-deterren...

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

 A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER [HYD]) is available for the treatment of chronic pain in appropriate patients. This study e...

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental ...

Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.

The U.S. Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) in an attempt to mitigate the prescription opioid epidemic. Many in the medical and pharmacy communit...

Pharmacokinetics of guaifenesin, pseudoephedrine and hydrocodone in a combination oral liquid formulation, administered as single and multiple doses in healthy Chinese volunteers, and comparison with data for individual compounds formulated as Antuss(®).

1. A new oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone is effective in improving the symptoms of common cold. The pharmacokinetic properties of the individual componen...

Search Whole site using Google

Quick Search
Advertisement Advertisement